Krystal Biotech

139 articles about Krystal Biotech

• Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

  4/4/2024

  Krystal Biotech, Inc. announced that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 and interleukin-2, the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.

• Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

  2/28/2024

  Krystal Biotech, Inc. announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6.

• Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

  2/26/2024

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

• Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

  2/20/2024

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. markets.

• Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

  2/8/2024

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced data on the compassionate use of beremagene geperpavec (B-VEC), administered as an eyedrop to treat a patient with dystrophic epidermolysis bullosa (DEB) with cicatrizing conjunctivitis has been published in the New England Journal of Medicine (NEJM).

• 

  Eyedrop Version of Krystal’s Gene Therapy Vyjuvek Restores Sight in Teen

  2/8/2024

  Under the FDA’s compassionate use program, an eyedrop formulation of Krystal Biotech’s Vyjuvek restored the vision of a teenager with the rare genetic disease dystrophic epidermolysis bullosa.

• Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

  2/1/2024

  Krystal Biotech, Inc. today announced that the Company will participate in the Guggenheim 6th Annual Biotechnology Conference, which takes place in New York on February 7-8.

• Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

  1/4/2024

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J3401) for VYJUVEK® (beremagene geperpavec-svdt), the first U.S. Food and Drug Administration-approved treatment for dystrophic epidermolysis bullosa (DEB).

• Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

  12/19/2023

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB).

• Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

  11/27/2023

  Krystal Biotech, Inc. today announced that the Company’s Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt, also known as B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) has been validated and is now under CHMP review.

• Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

  11/9/2023

  Krystal Biotech, Inc. announced that the Company will participate in the Stifel 2023 Healthcare Conference in New York.

• Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

  11/6/2023

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today reported financial results and key business updates for the third quarter ended September 30, 2023.

• Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

  10/30/2023

  Krystal Biotech, Inc. will report its third quarter 2023 financial results on Monday, November 6, 2023, prior to the open of U.S. markets.

• Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

  9/28/2023

  Krystal Biotech, Inc. announced that the Company will participate in the Chardan 7th Annual Genetic Medicines Conference in New York.

• Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

  9/21/2023

  Krystal Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD).

• Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

  9/5/2023

  Krystal Biotech, Inc. announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for KB408 for the treatment of alpha-1 antitrypsin deficiency.

• Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

  8/21/2023

  Krystal Biotech, Inc. announced that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million.

• Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

  8/7/2023

  Krystal Biotech, Inc. reported financial results and key operational progress updates for the second quarter ended June 30, 2023.

• Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

  7/26/2023

  Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it has expanded its R&D pipeline to oncology and that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application of its lead oncology drug candidate KB707 for the treatment of locally advanced or metastatic solid tumor malignancies.

• Krystal Biotech to Present at Upcoming June 2023 Investor Conferences

  6/5/2023

  Krystal Biotech, Inc. a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the Company will participate in the following upcoming investor conferences.